Howe & Rusling’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Howe & Rusling’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$49.3K	Sell	386 -50	-11%	-$6.24K	﹤0.01%	364
2025 Q4	$53.2K	Buy	436 +50	+13%	+$5.73K	﹤0.01%	366
2025 Q3	$38.7K	Hold	386	–	–	﹤0.01%	358
2025 Q2	$32K	Hold	386	–	–	﹤0.01%	369
2025 Q1	$31.3K	Sell	386 -133	-26%	-$11.9K	﹤0.01%	340
2024 Q4	$46.7K	Buy	519 +19	+4%	+$1.84K	﹤0.01%	318
2024 Q3	$49.4K	Buy	+500	New	+$49.1K	﹤0.01%	301
2022 Q2	–	Sell	-18	Closed	-$2K	–	1170
2022 Q1	$2K	Buy	+18	New	+$1.66K	﹤0.01%	898
2020 Q3	–	Sell	-65	Closed	-$7K	–	880
2020 Q2	$7K	Buy	65 +27	+71%	+$2.66K	﹤0.01%	495
2020 Q1	$3K	Buy	+38	New	+$3.37K	﹤0.01%	598
2019 Q1	–	Sell	-400	Closed	-$29K	–	896
2018 Q4	$29K	Buy	400 +100	+33%	+$8.06K	0.01%	305
2018 Q3	$29K	Buy	+300	New	+$29.1K	﹤0.01%	341

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Howe & Rusling's XBI Position: Q1 2026 in Review

Howe & Rusling reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 11% in Q1 2026, selling an estimated $6.24K and leaving 386 shares worth $49.3K. The position accounts for ﹤0.01% of the portfolio, ranked #364.

Howe & Rusling first reported a position in XBI in Q3 2018 and has held it in 12 quarters since. The position peaked at $53.2K in Q4 2025. 815 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

Howe & Rusling held 386 shares of State Street SPDR S&P Biotech ETF worth $49.3K as of Q1 2026.
Howe & Rusling sold 50 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $6.24K.
State Street SPDR S&P Biotech ETF made up ﹤0.01% of Howe & Rusling's portfolio in Q1 2026, its #364 holding.
Howe & Rusling first reported a position in State Street SPDR S&P Biotech ETF in Q3 2018 and has held it in 12 quarters since.
Howe & Rusling's State Street SPDR S&P Biotech ETF position peaked at $53.2K in Q4 2025.
815 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Howe & Rusling's 13F filing for Q1 2026, filed 28 Apr 2026.